Pfizer secures FDA approval for Velsipity to treat active ulcerative colitis in adults
Velsipity is an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, approved by the US FDA to treat moderately…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Oct 23
Velsipity is an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, approved by the US FDA to treat moderately…
13 Oct 23
Braftovi plus Mektovi is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with…
09 Oct 23
The Type II extension of indication application seeks approval for Rybrevant combo as a first-line treatment of NSCLC…
20 Sep 23
Litfulo works by irreversibly and selectively inhibiting JAK3 and the TEC family of kinases by blocking γ-common cytokine…
19 Sep 23
Cabotegravir is approved for use in combination with safer sex practices as a pre-exposure prophylaxis (PrEP) method and…
12 Sep 23
Pfizer and BioNTech’s updated Covid-19 vaccine, Comirnaty 2023-2024, and Moderna’s Spikevax were indicated for people aged 12 years…
08 Sep 23
Ervebo is a live recombinant viral vaccine that has a VSV backbone removed for the VSV envelope glycoprotein…
01 Sep 23
The FDA has approved the firm’s ANDA for Lisdexamfetamine Dimesylate Capsules 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, and…
29 Aug 23
The sNDA filing was based on the data from Cohort 1 of the late-stage THOR trial in which…
25 Aug 23
Japan’s MHLW expands Soliris’ indication to include children who are anti-acetylcholine receptor (AChR) antibody-positive, for whom high-dose intravenous…